TMCI Stock May Gain From the Limited Release of the Percuplasty System

Zacks01-07 00:08

Treace Medical Concepts, Inc. TMCI recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion Correction System and Procedure. This ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501263654?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 00:08","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2501263654","market":"us","top_or_hot":-1,"title":"TMCI Stock May Gain From the Limited Release of the Percuplasty System","media":"Zacks","content":"<div>\n<p>Treace Medical Concepts, Inc. TMCI recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion Correction System and Procedure.\nThis ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tmci-stock-may-gain-limited-160800388.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TMCI Stock May Gain From the Limited Release of the Percuplasty System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTMCI Stock May Gain From the Limited Release of the Percuplasty System\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 00:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tmci-stock-may-gain-limited-160800388.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Treace Medical Concepts, Inc. TMCI recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion Correction System and Procedure.\nThis ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tmci-stock-may-gain-limited-160800388.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0170899867.USD","symbol_name":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/tmci-stock-may-gain-limited-160800388.html","article_id":"2501263654","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501263654","pubTimestamp":1736179680,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Treace Medical Concepts, Inc. TMCI recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion CorrectionSystem and Procedure.This development follows Treace Medical's recent introduction of the Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, and the SpeedPlate Rapid Compression Implants, an innovative fixation platform versatile across various foot procedures.The Percuplasty Percutaneous 3D Bunion CorrectionSystem is anticipated to be fully commercialized in the second half of 2025.Following the announcement, shares of the company closed flat at $7.90 on Friday. In the past year, TMCI’s shares have lost 37.5% against the industry’s growth of 3.9%. The S&P 500 has gained 24.4% in the same time frame.The rising prevalence of bunions, combined with an increasing number of procedures to treat the condition globally, is e","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4539":"次新股","ABT":"雅培","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","MASI":"麦斯莫医疗","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4592":"伊斯兰概念","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4585":"ETF&股票定投概念","SG9999002224.SGD":"Allianz Global High Payout SGD","TMCI":"Treace Medical Concepts, Inc.","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","ARAY":"精确射线","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4566":"资本集团","BK4082":"医疗保健设备","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4568":"美国抗疫概念","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","BK4504":"桥水持仓","BK4581":"高盛持仓","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC"},"translate_title":"TMCI库存可能受益于Percuplasty系统的有限释放","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARAY":1,"TMCI":1,"MASI":1,"ABT":1},"content_text":"Treace Medical Concepts, Inc. TMCI recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion Correction System and Procedure.\nThis development follows Treace Medical's recent introduction of the Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, and the SpeedPlate Rapid Compression Implants, an innovative fixation platform versatile across various foot procedures.\nThe Percuplasty Percutaneous 3D Bunion Correction System is anticipated to be fully commercialized in the second half of 2025.\nLikely Trend of TMCI Stock Following the News\nFollowing the announcement, shares of the company closed flat at $7.90 on Friday. In the past year, TMCI’s shares have lost 37.5% against the industry’s growth of 3.9%. The S&P 500 has gained 24.4% in the same time frame.\nTreace Medical could likely witness a stock price boost with the limited launch of the new Percuplasty System, targeting the high-demand bunion surgery market. This innovative, minimally invasive system offers faster recovery and less pain, making it appealing to surgeons and patients. Alongside other recent product launches, this positions Treace Medical for growth by expanding its market share and revenues, likely attracting more investor interest if the rollout is successful. Hence, we expect this news to bolster investor confidence and create upward momentum in TMCI's share price in the long term.  \nMeanwhile, TMCI currently has a market capitalization of $492.2 million. The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $207.6 million, indicating 10.9% growth from the fiscal 2023 reported figure.\nImage Source: Zacks Investment Research\nDetails on the TMCI’s Percuplasty System\nThe Percuplasty System is a new medical innovation by Treace Medical, designed for minimally invasive correction of bunion deformities. It allows surgeons to perform precise 3D corrections through small, cosmetically appealing incisions, reducing the pain, swelling, and recovery time typically associated with traditional bunion surgeries. This advanced approach aligns with the growing demand for less invasive medical procedures, making it a game-changer in the field of foot and ankle surgery.\nFor Treace Medical, the Percuplasty System opens doors to a large and growing market. Nearly 450,000 bunion surgeries are performed annually in the United States, with 70% involving metatarsal osteotomies. By addressing this high-volume segment with a differentiated product, Treace Medical can attract more surgeons, grow its customer base, and significantly boost revenues.\nFavorable Industry Prospects for TMCI\nPer a report by Grand View Research, the global bunion correction systems market size is expected to reach $1.2 billion by 2030, witnessing a CAGR of 6.9% from 2023 to 2030.\nThe rising prevalence of bunions, combined with an increasing number of procedures to treat the condition globally, is expected to propel the market growth. The rising prevalence of the condition among the adult population is a key factor that is projected to positively impact market growth.\nMore on TMCI’s Other Recent Product Developments\nIn December 2024, TMCI announced the successful completion of the first cases utilizing SpeedPlate MicroQuad implants. The MicroQuad implant builds on the SpeedPlate platform, offering fast titanium compression fixation. Its unique design provides multiple fixation points for strong, stable support and dynamic compression. A one-inch incision supports minimally invasive techniques, making it ideal for precise and less invasive surgeries.\nIn the same month, Treace Medical announced the successful completion of the first cases combining IntelliGuide PSI technology with the Adductoplasty System for a CT-based, patient-specific correction personalized to the patient’s unique midfoot deformity. The IntelliGuide PSI, with RedPoint technology, is the first system to offer personalized surgical guidance for bunion and midfoot deformities. Using AI, it turns a patient’s CT scan into a surgical plan and creates a 3D-printed cut guide tailored to the patient, enabling precise and efficient surgeries.\nTMCI’s Zacks Rank & Stocks to Consider\nTMCI carries a Zacks Rank #4 (Sell) at present.\nSome better-ranked stocks in the broader medical space are Masimo MASI, Accuray ARAY and Abbott Laboratories ABT.\nMasimo, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 11.8% for 2025. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nMASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 31.7% against the industry’s 1% decline in the past six months.\nAccuray, carrying a Zacks Rank #2 at present, has an estimated growth rate of 1200% for 2025. Its earnings missed estimates in three of the trailing four quarters and met in one, delivering an average negative surprise of 141.97%.\nARAY’s shares have gained 8.8% against the industry’s 1% decline in the past six months.\nAbbott, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 10% for 2025. It delivered a trailing four-quarter average earnings surprise of 1.64%.\nABT’s shares have risen 8.5% in the past six months compared with the industry’s 7.2% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbott Laboratories (ABT) : Free Stock Analysis Report\nAccuray Incorporated (ARAY) : Free Stock Analysis Report\nMasimo Corporation (MASI) : Free Stock Analysis Report\nTreace Medical Concepts, Inc. (TMCI) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501263654"}